X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PAS-004 is is a small molecule allosteric inhibitor of MEK 1/2. It is being evaluated for the treatment of neurofibromatosis type 1 and other cancer indications.
Lead Product(s): PAS-004
Therapeutic Area: Oncology Product Name: PAS-004
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Pasithea Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
VYD222 was engineered from adintrevimab (ADG20), which provided neutralizing protection against SARS-CoV-2 for all variants of concern until the emergence of the Omicron BA.2 strain and its sublineages.
Lead Product(s): VYD222
Therapeutic Area: Infections and Infectious Diseases Product Name: VYD222
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Invivyd
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
OLP-1002 is an SCN9A antisense peptide nucleic acid (PNA) and selectively inhibits the expression of Nav1.7 sodium channel, and therefore expected to replicate much of the phenotype of people with SCN9A channelopathy.
Lead Product(s): OLP-1002
Therapeutic Area: Musculoskeletal Product Name: OLP-1002
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: OliPass
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
In the study NP-120 (Ifenprodil), demonstrated 65% of patients had stable or improved forced vital capacity (“FVC”) over the 12-week treatment period with statistical significance when compared to an anticipated placebo effect of 40%.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Algernon Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
SBI-100, a proprietary prodrug of tetrahydrocannabinol (“THC”), is a topical formulation under development to treat glaucoma. SBI-100 enables enhanced local delivery of the drug into the eye, reduced systemic side effects and the potential for neuroprotection.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Ophthalmology Product Name: SBI-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Skye Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 03, 2022
Details:
The first in human clinical trial is randomized, double-blind, vehicle controlled study to determine the safety, tolerability, PK and efficacy of twice daily application of topical BioLexa™ lotion, in adult and adolescent patients with mild to moderate AD.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Hoth Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Details:
XW003, a potential candidate for the treatment of non-alcoholic steatohepatitis (NASH), has been approved by China NMPA for clinical trial.
Lead Product(s): XW003
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: XW003
Highest Development Status: Phase IProduct Type: Peptide
Recipient: Sciwind
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2021
Details:
The new clinical trial is designed to evaluate the use of GP1681 as a potential new medicine to treat the severe immune response to COVID-19.
Lead Product(s): GP1681
Therapeutic Area: Immunology Product Name: GP1681
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: CytoAgents
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The company said it seeks to expand the use of Panaphix to cover COVID-19 treatment through this proposed clinical trial.
Lead Product(s): Panaphix
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
